Suppr超能文献

普通外科中深静脉血栓形成的预防与治疗。

Prophylaxis and treatment of deep vein thrombosis in general surgery.

作者信息

Gutt Carsten N, Oniu Traian, Wolkener Frédéric, Mehrabi Ari, Mistry Shilu, Büchler Markus W

机构信息

Department of General Surgery, Ruprecht-Karls-University, Im Neuenheimer Feld 110, D-62120 Heidelberg, Germany.

出版信息

Am J Surg. 2005 Jan;189(1):14-22. doi: 10.1016/j.amjsurg.2004.04.009.

Abstract

BACKGROUND

Patients undergoing general surgery present an inherent risk of deep vein thrombosis (DVT). Evidence-based strategies for prevention and treatment of DVT should be continuously upgraded on the basis of good-quality recent trials.

DATA SOURCES

Articles were identified using MEDLINE, EMBASE, and the Cochrane Library databases (January 1980 to July 2003). Randomized clinical trials and meta-analyses in which different prophylactic and treatment methods were compared for general surgery patients were selected.

CONCLUSIONS

In general surgery, low-molecular weight heparins (LMWHs) are relied upon more and more for prophylaxis and initial anticoagulant treatment of DVT, because of their multiple advantages in efficacy, safety, and convenience in handling. For cost-effective reasons, full-dose vitamin K antagonists are still preferred as the standard long-term anticoagulation method, while LMWHs represent the exception. Long-term use of low-intensity warfarin should be considered a new standard of care for the management of venous thrombosis. Compared to LMWH, the new anticoagulant molecules fondaparinux and ximelagatran seem to have similar efficacy in the treatment of venous thromboembolism, but they have a 2-fold increased efficacy in its prophylaxis. Clinical implementation of these new anticoagulant molecules depends on their cost-effectiveness; however, they have the potential to become the treatment of choice in the next decade. Thrombolysis has an unacceptable risk of hemorrhagic complications when used in the treatment of postoperative DVT. Furthermore, there are no data to prove that thrombolysis reduces the incidence of postthrombotic syndrome (PTS), despite early and complete recanalization achieved by thrombolysis. Surgical thrombectomy is only meant to decompress the venous hypertension consecutive to massive thrombosis (phlegmasia cerulea dolens) and thus to avoid venous gangrene. Other mechanical percutaneous thrombectomy devices are under evaluation. In selected cases, a combination treatment consisting of locoregional thrombolysis of the crurofemoral venous axis and mechanical thrombectomy of the pelvic venous axis achieves high rates of complete desobliteration.

摘要

背景

接受普通外科手术的患者存在深静脉血栓形成(DVT)的固有风险。基于循证的DVT预防和治疗策略应根据近期高质量试验不断更新。

数据来源

通过MEDLINE、EMBASE和Cochrane图书馆数据库(1980年1月至2003年7月)检索文章。选择对普通外科手术患者不同预防和治疗方法进行比较的随机临床试验和荟萃分析。

结论

在普通外科手术中,低分子量肝素(LMWHs)因其在疗效、安全性和使用便利性方面的多重优势,越来越多地用于DVT的预防和初始抗凝治疗。出于成本效益的原因,全剂量维生素K拮抗剂仍作为标准的长期抗凝方法被首选,而LMWHs为例外。长期使用低强度华法林应被视为静脉血栓形成管理的新护理标准。与LMWH相比,新型抗凝分子磺达肝癸钠和希美加群在治疗静脉血栓栓塞方面似乎具有相似的疗效,但在预防方面其疗效提高了两倍。这些新型抗凝分子的临床应用取决于其成本效益;然而,它们有可能在未来十年成为首选治疗方法。溶栓用于治疗术后DVT时存在不可接受的出血并发症风险。此外,尽管溶栓可实现早期和完全再通,但尚无数据证明溶栓可降低血栓形成后综合征(PTS)的发生率。手术取栓仅旨在缓解大量血栓形成(股青肿)后的静脉高压,从而避免静脉坏疽。其他机械性经皮取栓装置正在评估中。在特定病例中,由股腘静脉轴局部溶栓和盆腔静脉轴机械取栓组成的联合治疗可实现较高的完全再通率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验